A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Biliary Tract Carcinoma
- Ovarian Cancer
- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Research Site · Santa Monica, CA
- Research Site · Santa Rosa, CA
Maryland · 1
- Research Site · Baltimore, MD
Massachusetts · 1
- Research Site · Boston, MA
Missouri · 1
- Research Site · St Louis, MO
New Mexico · 1
- Research Site · Albuquerque, NM
New York · 1
- Research Site · Commack, NY
North Carolina · 1
- Research Site · Charlotte, NC
Pennsylvania · 1
- Research Site · Pittsburgh, PA
Texas · 1
- Research Site · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.